









Markets
/
Stocks
/
nasdaq-anvs
/

Annovis Bio Inc

ANVS

2.320USD

-0.030-1.28%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

45.21MMarket Cap

LossP/E TTM



Annovis Bio Inc

2.320

-0.030-1.28%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

280 / 506

Overall Ranking

470 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

13.750

Target Price

+485.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.

Overvalued

The company’s latest PE is -1.10, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.98M shares, decreasing 5.69% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 696.76K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.12, which is 27.33% below the recent high of -1.42 and -189.29% above the recent low of -3.24.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 280/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.60, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Annovis Bio Inc is 13.50, with a high of 20.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

13.750

Target Price

+485.11%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Annovis Bio Inc

ANVS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.41, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.51 and the support level at 2.20, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.41

Change

-0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.019

Neutral

RSI(14)

44.004

Neutral

STOCH(KDJ)(9,3,3)

31.892

Sell

ATR(14)

0.107

Low Volatility

CCI(14)

-22.031

Neutral

Williams %R

64.516

Sell

TRIX(12,20)

-0.359

Sell

StochRSI(14)

8.575

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.350

Sell

MA10

2.364

Sell

MA20

2.342

Sell

MA50

2.550

Sell

MA100

2.412

Sell

MA200

2.821

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 30.66%, representing a quarter-over-quarter decrease of 26.35%. The largest institutional shareholder is The Vanguard, holding a total of 696.76K shares, representing 3.58% of shares outstanding, with 8.45% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Hoffman (Michael B)

1.67M

+1.52%

Maccecchini (Maria-Luisa)

1.11M

+4.31%

Heights Capital Management, Inc.

1.00M

The Vanguard Group, Inc.

Star Investors

647.92K

+38.96%

Geode Capital Management, L.L.C.

152.61K

+53.28%

Susquehanna International Group, LLP

127.70K

+130.88%

Consilium Associates

97.82K

-0.71%

BlackRock Institutional Trust Company, N.A.

99.49K

-1.28%

White (Mark K.)

61.17K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.98, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.66. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.